Pimecrolimus

10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus

5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis

Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca

Open Label Study of Long Term Treatment of Pediatric Treatment of Atopic Dermatitis With Pimecrolimus Cream 1% Within a Usual Clinical Setting

1% Topical Pimecrolimus Cream for the Treatment of the Rash Associated With ERBITUX

Assessment of Pruritus Improvement With Pimecrolimus Treatment on the Areas Affected by Mild-to-moderate AD, in Patients 2- to 11- Year-old

Open-label Study to Investigate Systemic Exposure in Adult and Pediatric Atopic Dermatitis Patients Treated 8.5 Days With Pimecrolimus Cream 1% Under Occlusion

Effect of Pimecrolimus Cream on Cathelicidin Levels in Subjects With Eczema

Safety and Efficacy of Pimecrolimus Cream 1% in Atopic Disease Modification

Pimecrolimus Cream 1% (Elidel®) and Medicated Device Cream (EletoneTM) in the Treatment and Maintenance of Atopic Dermatitis.

Combination Therapy for Atopic Dermatitis

Evaluation of the Antipruritic Effect of Elidel (Pimecrolimus) in Non-atopic Pruritic Disease

Standardized Time- and Score-oriented Treatment of Moderate and Severe Atopic Dermatitis

Efficacy of Elidel Cream on Erosive Oral Lichen Planus

Comparison of Pimecrolimus Cream 1% Twice-Daily to Once-Daily Dosing in the Management of Atopic Dermatitis in Pediatric Subjects

Pimecrolimus Cream 1% in Adult Patients With Perioral Dermatitis

Quality of Life Study in Adults With Facial Eczema

Steroid-Sparing Effect With Pimecrolimus in Pediatric Patients With Atopic Dermatitis

Efficacy and Safety of Pimecrolimus Cream 1% in Patients (2 to 11 Years Old) With Mild to Moderate Facial Atopic Dermatitis

Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) Patients